247936-61-4

Upstream product

• 20915-80-4 3,4-Dihydro-6-methoxy-2-(pyrrolidin-1-yl)naphthalene 
• 110-89-4 piperidine 
• 2472-22-2 6-methoxy-2-tetralone 
• 100-39-0 benzyl bromide 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 
• 247936-62-5 3,4-dihydro-6-methoxy-1-(phenylmethylidenyl)-2-naphthalenone 

Downstream Products

• 305830-61-9 1-(R)-benzyl-6-methoxy-1-(S)-(3-oxo-butyl)-3,4-dihydro-1H-naphthalen-2-one 
• 418772-26-6 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-vinyl-, [2R-(2α,4aα,10aβ)] 
• 418772-29-9 Ethanimidamide, N-hydroxy-2-[[4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl]-oxy], [4bS-(4bα,7α,8aβ)] 
• 305822-66-6 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-, [2S-(2α,4aβ,10aα)]- 
• 305823-36-3 [2'R-(2'α,4'aα,10'aβ)]-3',4',4'a,9',10',10'a-hexahydro-4'a-(phenylmethyl)-spiro[oxirane-2,2'(1'H)-phenanthren]-7'-ol 
• 305822-75-7 [4bS-(4bα,7α,8aβ)]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-N-[3-(1H-imidazol-1-yl)propyl]-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenecarboxamide 
• 305822-73-5 C₂₉H₂₉NO 
• 305822-71-3 [4bS-(4bα,7α,8aβ)]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenecarboxylic acid methyl ester 
• 305830-52-8 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(trifluoromethyl)-, (2R,4aS,10aR)- 
• 305821-96-9 [4bS-(4bα,7α,8aβ)]-4b,5,8,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-N-(3-pyridinylmethyl)-2-phenanthrenecarboxamide 

Relevant academic research and scientific papers

GLUCOCORTICOID RECEPTOR MODULATORS

The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compos

Glucocorticoid receptor modulators

The present invention provides non-steroidal compounds of Formula I, including prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides processes for preparing these compounds.

N-SUBSTITUTED AMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS

beta -Aminotetralin derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a beta -aminotetralin derivative as the active ingredient are described. The beta -aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.

The synthesis of novel cis-α-substituted-β-aminotetralins

Teteralones were converted, in 1 to 3 steps, to α-substituted tetralones. Subsequent reductive amination with ammonium acetate/sodium cyanoborohydride gave the corresponding α-substituted-β-aminotetralins, on a multigram scale, with minimal chromatography for the entire transformation.

Glucocorticoid receptor modulators

The present invention provides non-steroidal compounds of Formula I, and prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides processes for preparing these compounds.

Glucocorticoid receptor modulators

The present invention provides non-steroidal compounds of Formula I, including prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides processes for preparing these compounds.

Glucocorticoid receptor modulators

The present invention provides non-steroidal compounds of Formula I, and prodrugs and pharmaceutically acceptable salts thereof, which are selective modulators (e.g., agonists, partial agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides processes for preparing these compounds.

Glucocorticoid receptor modulators

The present invention provides non-steroidal compounds of formula I which are selective modulators (i.e., agonists and antagonists) of a steroid receptor, specifically, the glucocorticoid receptor. The present invention also provides pharmaceutical compositions containing these compounds and methods for using these compounds to treat animals requiring glucocorticoid receptor agonist or antagonist therapy. Glucocorticoid receptor modulators are useful to treat diseases, such as obesity, diabetes, inflammation and others as described below. The present invention also provides intermediates and processes for preparing these compounds. STR1

Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists

An approach to the computer-assisted, pharmacophore design of nonsteroidal templates for the glucocorticoid receptor (GR) that contained an element of pseudo-C2 symmetry was developed. The enatiomer of the initial design, 1Ra, and not the designed molecul

N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor

β-Aminotetralin derivatives of the formula: which are ligands for the neuropeptide Y Y5 (NPY5) receptor, methods of preparation and pharmaceutical compositions containing a β-aminotetralin derivative as the active ingredient are described. The 62 -aminotetralins are useful in the treatment of disorders and diseases associated with NPY receptor subtype Y5.